Justin McCue

Chief Technical Officer • Avectas

Justin leads the overall technological and scientific strategy for Avectas and its Solupore® technology. Solupore® utilizes a non-viral, physiochemical transfection process which enables complex, multi-step editing for the production of next-generation cell therapy products. Prior to joining Avectas, Justin was the Vice President of Technical Operations at Repertoire Immune Medicines where he led CMC development and clinical manufacturing of their multi-targeted antigen-specific T-cell platform. Justin has spent more than 20 years in the cell therapy and biopharma industry, including roles at Juno/Celgene and Biogen. Justin earned a BS from University of California at Berkeley and PhD from M.I.T. in Chemical Engineering.

Also Speaking

Marco Ruella

Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies • University of Pennsylvania

Bryan Poltilove

Operating Partner • Broadoak Capital Partners

Matthew Hewitt

Executive Director, Scientific Services, Cell & Gene Therapy (CGT) • Charles River

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.